However, handful of evidence clearly demonstrates that overexpression of NM23-H1 is associated with disease progression and poor patient survival in thyroid carcinomas, cervical cancer, neuroblastomas and osteosarcoma patients46. Here, NME1 is linked to cervical cancer.